Home › Cancro metastatico › Maryland
Studi clinici su Cancro metastatico nello stato di Maryland
47 studi su Cancro metastatico cercano partecipanti presso sedi nello stato di Maryland.
Città nello stato di Maryland
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- e altri 1
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Maryland Oncology, Columbia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07562152Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Greater Baltimore Medical Center, Baltimore
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222800Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, P.A., Brandywine
- e altri 5
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- JHU Oncology Central Kit Services, Baltimore
- Johns Hopkins Hospital, Baltimore
- Oncology Investigational Drug Service (IDS), Baltimore
- e altri 1
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- John Hopkins University, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06915753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Johns Hopkins Hospital, Baltimore
- James M Stockman Cancer Institute, Frederick
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06606990The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 2
Età da 18 a 98 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04927416Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT03907475The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 2
Età da 18 a 90 · Tutti i sessi · Aggiornato il 9 set 2026 · NCT03841617NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Johns Hopkins, Baltimore
In reclutamentoFase 1
Età 19 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07563829A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 2
Età da 18 a 72 · Tutti i sessi · Aggiornato il 31 ago 2026 · NCT02133196Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05687136FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Johns Hopkins Kimmel Cancer Center, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT05614739A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Baltimore
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 ago 2026 · NCT05691517Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 29 lug 2026 · NCT07044336REMASTer: REcurrent Brain Metastases After SRS Trial
- University of Maryland, Baltimore
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 giu 2026 · NCT05124912E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 giu 2026 · NCT05686226Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Advanced Molecular Imaging and Therapy, Glen Burnie
- United Theranostics - Chesapeake, Glen Burnie
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 giu 2026 · NCT05283330Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Johns Hopkins University, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2026 · NCT06040541Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- University of Maryland, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT04617522A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- John Hopkins University, Baltimore
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 27 mag 2026 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- American Oncology Partners, P.A., Bethesda
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mag 2026 · NCT06757634Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Johns Hopkins University, Baltimore
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 mag 2026 · NCT05379985Studying TAK-243 in Patients With Advanced Cancer
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mag 2026 · NCT06223542Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- The Center for Cancer and Blood Disorders, Bethesda
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 mag 2026 · NCT06697301A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Johns Hopkins University, Baltimore
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT07020221A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06064877Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
In reclutamentoFase 2/3
Età 18 e oltre · Uomini · Aggiornato il 8 apr 2026 · NCT04787744Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.